Achaogen Raises $65 Million

Achaogen, a San Francisco-based developer of antibiotics to treat life-threatening, multi-drug resistant bacterial infections, has raised $65 million in Series C funding. Frazier Healthcare Ventures led the round, and was joined by Alta Partners and return backers 5AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust. The company previously raised around $42 million.

North AmericaUSBriefs